Drug delivery via nanoparticle-based carriers has shown promising pharmacological improvements in cancer therapy [1, 2] Nanoparticle albumin-bound paclitaxel (Abraxane) has been approved by FDA for use in patients with metastatic breast cancer and Non-small-cell lung carcinoma (NSCLC) [3, 4]. The gene discussed is ALB; the disease is non-small cell lung carcinoma.